There were no statistically significant differences in the score of FOXP3 + cells between 30 DCIS patients with a poor outcome and 11 patients with DCIS with a good outcome (median 0% vs. 0%, respectively, p = 0.513). This evidence concerns the gene FOXP3 and ductal breast carcinoma in situ.